PolarCool AB

POLAR

SE0012570422

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets			5-day change	1st Jan Change
- ^SEK	-.--%		-.--%	-.--%

06-13	PolarCool’s PolarCap Product Gets Approval in Australia	MT
05-29	PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

PolarCool AB announced that it has received SEK 0.60638 million in funding

May 12, 2022

On May 13, 2022, PolarCool AB (publ) closed the transaction. The company issued 233,223 shares for gross proceeds of SEK 606,380. The share capital of the company increased to SEK 51,904.31628995547.

Latest news about PolarCool AB

PolarCool’s PolarCap Product Gets Approval in Australia	06-13	MT
PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-23	CI
PolarCool to Offer Concussion Therapy to United Rugby Championship League's Cardiff Rugby	02-21	MT
PolarCool Signs Concussion Treatment Deal with EC Klagenfurter	02-16	MT
PolarCool, Neurovision Sport and Performance Sign Strategic Partnership Deal	02-07	MT
PolarCool Inks Deal with Swiss Professional Ice Hockey Club for Concussion Treatment	01-30	MT
PolarCool to Provide Concussion Treatment to German Ice Hockey League Team	01-09	MT
PolarCool AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
PolarCool Strikes Deals with Swedish Hockey League’s Clubs for Concussion Product; Shares Drop	11-21	MT
PolarCool AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-26	CI
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
PolarCool Secures Two-Year Deal With Danish Hockey Club for PolarCap; Shares Sink 11%	23-01-20	MT
PolarCool AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
PolarCool Signs Supply Agreement with Welsh Football Federation	22-10-24	MT
PolarCool Developed PolarCap	22-10-20	CI
PolarCool Up 11% Amid Two-Year Deal with London Irish Rugby Team	22-10-04	MT
PolarCool To Supply PolarCap to Ice Hockey Team Kalmar HC	22-09-28	MT
PolarCool AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
PolarCool Drops 12% After Three-year Deal With Swedish Hockey Team	22-06-17	MT
PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
PolarCool AB announced that it has received SEK 0.60638 million in funding	22-05-12	CI
PolarCool AB announced that it expects to receive SEK 0.60638 million in funding	22-05-03	CI
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-25	CI

Polarcool AB is a Sweden-based medical device company specializing in sports medicine. The Company focuses on of concussive and sub-concussive brain injuries. It develops a portable brain cooling device called PolarCap System. The PolarCap System consists of a cooling unit and a silicone-based cooling cap alongside neoprene insulation, cooling the head and neck via a circulating coolant during a procedure that takes approximately 45-60 minutes. The idea behind it is the reduction of brain temperature of individuals suffering from a concussion or participating in an activity where repetitive head impact occurs, such as contact and combat sports, in order to prevent or limit long term cognitive impairment. The device undergoes preclinical cohort study for concussion among hockey players and a preclinical study for indication of sub-concussive repetitive head impact among American football players.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Medical Devices

	1st Jan change	Capi.
POLARCOOL AB	-.--%	314K
MIMEDX GROUP, INC.	-21.66%	1.01B
NIBEC CO., LTD.	-16.21%	134M
KIM FOREST ENTERPRISE CO., LTD.	+1.63%	58.14M
COLLPLANT BIOTECHNOLOGIES LTD.	-24.18%	55.5M
BONUS BIOGROUP LTD.	-1.80%	50.96M